AVE 3247
Latest Information Update: 17 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Anti-ischaemics; Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Thrombosis
Most Recent Events
- 23 May 2006 Phase-I clinical trials in Thrombosis in France (unspecified route)
- 01 Mar 2005 Preclinical trials in Acute coronary syndromes in USA (unspecified route)
- 01 Mar 2005 Preclinical trials in Thrombosis in France (unspecified route)